BRPI1008300B1 - Processo de purificação de daptomicina - Google Patents
Processo de purificação de daptomicina Download PDFInfo
- Publication number
- BRPI1008300B1 BRPI1008300B1 BRPI1008300-6A BRPI1008300A BRPI1008300B1 BR PI1008300 B1 BRPI1008300 B1 BR PI1008300B1 BR PI1008300 A BRPI1008300 A BR PI1008300A BR PI1008300 B1 BRPI1008300 B1 BR PI1008300B1
- Authority
- BR
- Brazil
- Prior art keywords
- daptomycin
- chromatography column
- process according
- elution buffer
- reverse phase
- Prior art date
Links
- 229960005484 daptomycin Drugs 0.000 title claims abstract description 69
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 title claims abstract description 68
- 108010013198 Daptomycin Proteins 0.000 title claims abstract description 67
- 238000000746 purification Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000011347 resin Substances 0.000 claims description 30
- 229920005989 resin Polymers 0.000 claims description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 27
- 150000001450 anions Chemical class 0.000 claims description 20
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 20
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 239000012149 elution buffer Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 238000004587 chromatography analysis Methods 0.000 claims description 12
- 238000005352 clarification Methods 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 9
- 238000011210 chromatographic step Methods 0.000 claims description 8
- 238000001728 nano-filtration Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004606 Fillers/Extenders Substances 0.000 claims description 2
- 238000001223 reverse osmosis Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 108010028921 Lipopeptides Proteins 0.000 abstract description 2
- 239000000872 buffer Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000010828 elution Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000013622 capto Q Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 229940021392 cubicin Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15366009P | 2009-02-19 | 2009-02-19 | |
| US61/153,660 | 2009-02-19 | ||
| PCT/NO2010/000066 WO2010095953A1 (en) | 2009-02-19 | 2010-02-19 | Process for purifying lipopeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1008300A2 BRPI1008300A2 (pt) | 2016-03-15 |
| BRPI1008300A8 BRPI1008300A8 (pt) | 2021-05-11 |
| BRPI1008300B1 true BRPI1008300B1 (pt) | 2021-07-13 |
Family
ID=42116034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008300-6A BRPI1008300B1 (pt) | 2009-02-19 | 2010-02-19 | Processo de purificação de daptomicina |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9150894B2 (enExample) |
| EP (1) | EP2398817B2 (enExample) |
| JP (1) | JP5752609B2 (enExample) |
| KR (1) | KR101666144B1 (enExample) |
| CN (1) | CN102325785B (enExample) |
| AU (1) | AU2010216475B2 (enExample) |
| BR (1) | BRPI1008300B1 (enExample) |
| CA (1) | CA2748932C (enExample) |
| DK (1) | DK2398817T4 (enExample) |
| ES (1) | ES2543457T5 (enExample) |
| HR (1) | HRP20150761T4 (enExample) |
| HU (1) | HUE026818T2 (enExample) |
| IL (1) | IL214374A (enExample) |
| MX (1) | MX2011008621A (enExample) |
| PL (1) | PL2398817T5 (enExample) |
| PT (1) | PT2398817E (enExample) |
| RU (1) | RU2526391C2 (enExample) |
| SI (1) | SI2398817T2 (enExample) |
| UA (1) | UA105785C2 (enExample) |
| WO (1) | WO2010095953A1 (enExample) |
| ZA (1) | ZA201104848B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2526391C2 (ru) | 2009-02-19 | 2014-08-20 | Кселлия Фармасьютикалз Апс | Способ очистки липопептидов |
| CN102690329B (zh) * | 2011-03-25 | 2014-06-04 | 杭州九源基因工程有限公司 | 一种戈舍瑞林多肽的纯化生产方法 |
| CN102875652A (zh) * | 2011-07-13 | 2013-01-16 | 北大方正集团有限公司 | 一种分离纯化达托霉素的方法 |
| CN103159829B (zh) * | 2011-12-08 | 2014-11-05 | 北大方正集团有限公司 | 达托霉素的提取方法 |
| CN102675426B (zh) * | 2012-04-26 | 2013-12-11 | 杭州华东医药集团生物工程研究所有限公司 | 一种达托霉素的提取纯化方法 |
| CN102924572B (zh) * | 2012-11-12 | 2014-12-03 | 华北制药集团新药研究开发有限责任公司 | 一种高纯度达托霉素的制备方法 |
| CN104387444B (zh) * | 2014-11-13 | 2017-12-08 | 北大医药重庆大新药业股份有限公司 | 一种达托霉素杂质rs‑2高纯度样品的制备方法 |
| EP3233230B1 (en) * | 2014-12-15 | 2024-06-12 | Merck Patent GmbH | Target molecule capture from crude solutions |
| CN105001305A (zh) * | 2015-04-29 | 2015-10-28 | 利穗科技(苏州)有限公司 | 利用层析技术提取高纯度达托霉素的方法 |
| CN105481950B (zh) * | 2016-01-28 | 2019-01-04 | 丽珠集团福州福兴医药有限公司 | 一种达托霉素提取方法 |
| IT201600127655A1 (it) | 2016-12-16 | 2018-06-16 | Gnosis Spa | Processo per la purificazione di antibiotici lipopolipeptidici |
| CN108250270A (zh) * | 2016-12-29 | 2018-07-06 | 天津领世生物科技开发有限公司 | 一种从发酵液中富集提取达托霉素的方法 |
| CN112979756B (zh) * | 2019-12-13 | 2023-01-03 | 浙江昌海制药有限公司 | 达托霉素的提纯方法 |
| CN113004373B (zh) * | 2019-12-19 | 2024-08-13 | 鲁南制药集团股份有限公司 | 一种达托霉素的纯化方法 |
| RU2762182C1 (ru) * | 2020-12-08 | 2021-12-16 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" | Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения |
| CN113340691B (zh) * | 2021-06-05 | 2023-12-12 | 清华大学 | 一种提取海洋沉积物中不同赋存形态磷的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4537717A (en) | 1982-05-21 | 1985-08-27 | Eli Lilly And Company | Derivatives of A-21978C cyclic peptides |
| US4885243A (en) | 1984-10-09 | 1989-12-05 | Eli Lilly And Company | Process for producing A-21978C derivatives |
| US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
| ZA883887B (en) | 1987-06-10 | 1990-02-28 | Lilly Co Eli | Chromatographic purification process |
| US4874843A (en) | 1987-12-03 | 1989-10-17 | Eli Lilly And Company | Chromatographic purification process |
| JP2661790B2 (ja) * | 1990-11-27 | 1997-10-08 | 電気化学工業株式会社 | 入尿トリプシンインヒビターの精製方法 |
| ZA946122B (en) * | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| US5650496A (en) | 1995-04-14 | 1997-07-22 | Cephalon, Inc. | IGF-I purification process |
| US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| AU2002246688A1 (en) * | 2000-12-18 | 2002-07-30 | Altus Biologics Inc. | Methods for preparing purified daptomycin |
| US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| JP2010505874A (ja) * | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| WO2009144739A1 (en) * | 2008-05-26 | 2009-12-03 | Biocon Limited | Amorphous daptomycin and a method of purification thereof |
| RU2526391C2 (ru) | 2009-02-19 | 2014-08-20 | Кселлия Фармасьютикалз Апс | Способ очистки липопептидов |
| CN101899094B (zh) * | 2009-06-01 | 2012-11-21 | 安徽丰原发酵技术工程研究有限公司 | 一种高纯达托霉素的制备方法 |
-
2010
- 2010-02-19 RU RU2011137010/04A patent/RU2526391C2/ru active
- 2010-02-19 HU HUE10707694A patent/HUE026818T2/en unknown
- 2010-02-19 JP JP2011551028A patent/JP5752609B2/ja active Active
- 2010-02-19 CA CA2748932A patent/CA2748932C/en active Active
- 2010-02-19 WO PCT/NO2010/000066 patent/WO2010095953A1/en not_active Ceased
- 2010-02-19 MX MX2011008621A patent/MX2011008621A/es active IP Right Grant
- 2010-02-19 PL PL10707694T patent/PL2398817T5/pl unknown
- 2010-02-19 CN CN201080008292.3A patent/CN102325785B/zh active Active
- 2010-02-19 BR BRPI1008300-6A patent/BRPI1008300B1/pt active IP Right Grant
- 2010-02-19 KR KR1020117021714A patent/KR101666144B1/ko active Active
- 2010-02-19 HR HRP20150761TT patent/HRP20150761T4/hr unknown
- 2010-02-19 UA UAA201111075A patent/UA105785C2/uk unknown
- 2010-02-19 SI SI201030966T patent/SI2398817T2/sl unknown
- 2010-02-19 PT PT107076945T patent/PT2398817E/pt unknown
- 2010-02-19 DK DK10707694.5T patent/DK2398817T4/da active
- 2010-02-19 EP EP10707694.5A patent/EP2398817B2/en active Active
- 2010-02-19 ES ES10707694T patent/ES2543457T5/es active Active
- 2010-02-19 US US12/708,539 patent/US9150894B2/en active Active
- 2010-02-19 AU AU2010216475A patent/AU2010216475B2/en active Active
-
2011
- 2011-06-30 ZA ZA2011/04848A patent/ZA201104848B/en unknown
- 2011-08-01 IL IL214374A patent/IL214374A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008300B1 (pt) | Processo de purificação de daptomicina | |
| DK202100114Y4 (da) | Separation af 2’-FL fra en fermentationskulturopløsning | |
| US12060594B2 (en) | Separation of 2′-FL from a fermentation broth | |
| JP7566762B2 (ja) | 陰イオン交換クロマトグラフィーを使用した生物学的分子、例えばプラスミドｄｎａなどのための精製プロセス | |
| JP2009519245A (ja) | エキノカンジン型化合物の精製方法 | |
| WO2009144739A1 (en) | Amorphous daptomycin and a method of purification thereof | |
| JP2003508054A (ja) | チャンネル形成性タンパク質の製造方法 | |
| EP3668885B1 (en) | Method of purifying phycocyanin | |
| CN113004373B (zh) | 一种达托霉素的纯化方法 | |
| Quinn¹ | Chemistry of aqueous marine extracts: Isolation techniques | |
| BR112019012273A2 (pt) | processo para a purificação de antibióticos lipopolipeptídicos de caldos de cultura e usos de uma resina de troca catiônica | |
| US8609368B2 (en) | Process for purifying vancomycin wet body | |
| FI64508C (fi) | Foerfarande foer framstaellning av rent insulin saosom insulinav svin ur bukspottkoertlar | |
| CA2752784A1 (en) | Daptomycin formulation | |
| CN102453063B (zh) | 帕曲星b的分离方法 | |
| EP4190780A1 (en) | Method for extracting mupirocin | |
| Gu | Purification techniques for human growth hormone (hGH) and an hGH antagonist | |
| IT201800006314A1 (it) | Uso di resine a scambio cationico per la purificazione di antibiotici lipopolipeptidici |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |